Shots:

• The company initiates the P-I study to evaluate the safety and tolerability of BFI-751 vs in 210 healthy volunteers and their immune response across Australia and New Zealand
• The 1EPs of the study is to compare the PK of 751-BFI to the US & EU-Stelara following a single dose under the skin
• BFI-751 is a biosimilar drug referencing Stelara- indicated to treat CD- UC- PsO and PsA

to Ref: Prweb | Image: LinkedIn